Large Cell Neuroendocrine Carcinoma

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Molecular Partners
Molecular PartnersSchlieren-Zurich, Switzerland
1 program
1
[212Pb]Pb-MP0712Phase 1/21 trial
Active Trials
NCT07278479Recruiting138Est. Sep 2032

Trial Timeline

Clinical trial activity over time

2026
2027
2028
2029
2030
2031
Molecular Partners[212Pb]Pb-MP0712

Clinical Trials (1)

Total enrollment: 138 patients across 1 trials

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Start: Jan 2026Est. completion: Sep 2032138 patients
Phase 1/2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 138 patients
1 companies competing in this space